BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37314752)

  • 1. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma.
    Effenberger M; Waschina S; Bronowski C; Sturm G; Tassiello O; Sommer F; Zollner A; Watschinger C; Grabherr F; Gstir R; Grander C; Enrich B; Bale R; Putzer D; Djanani A; Moschen AR; Zoller H; Rupp J; Schreiber S; Burcelin R; Lass-Flörl C; Trajanoski Z; Oberhuber G; Rosenstiel P; Adolph TE; Aden K; Tilg H
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37314752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbial signatures of patients with primary hepatocellular carcinoma and their healthy first-degree relatives.
    Feng J; Wu Y; Dai P; Wang D; Liu L; Chai B
    J Appl Microbiol; 2023 Oct; 134(10):. PubMed ID: 37777841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
    Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Tang Y; Zhou H; Xiang Y; Cui F
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
    Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma.
    Lapidot Y; Amir A; Nosenko R; Uzan-Yulzari A; Veitsman E; Cohen-Ezra O; Davidov Y; Weiss P; Bradichevski T; Segev S; Koren O; Safran M; Ben-Ari Z
    mSystems; 2020 Jun; 5(3):. PubMed ID: 32546668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
    Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.
    Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A
    Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
    Yang J; He Q; Lu F; Chen K; Ni Z; Wang H; Zhou C; Zhang Y; Chen B; Bo Z; Li J; Yu H; Wang Y; Chen G
    Gut Microbes; 2023; 15(1):2201159. PubMed ID: 37089022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.